Investing.com - Financial Markets Worldwide

Takeda Pharmaceutical Co., Ltd. (4502)

Tokyo
Symbol
Exchange
Currency
4502·Tokyo·JPY
TAK·NYSE·USD
TKPHF·OTC Markets·USD
4502·Frankfurt·EUR
4502·TradeGate·EUR
TAKP34·B3·BRL
TKD·Vienna·EUR
Currency in JPY
4,296.0
+10.0(+0.23%)
Closed·

4502 Financial Summary

Key Ratios

P/E Ratio62.76
Price/Book0.98
Debt / Equity73.37%
Return on Equity1.52%
Dividend Yield4.62%
EBITDA1.23T
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2016
31/03
2017
31/03
2018
31/03
2019
31/03
2020
31/03
2021
31/03
2022
31/03
2023
31/03
2024
31/03
2025
31/03
Income Statement
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa3,197,8123,569,0064,027,4784,263,7624,581,551
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa2,184,1572,441,6982,774,3152,832,2573,010,132
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa424,047600,062619,667499,475562,936
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa376,005230,059317,017144,067107,928
Balance Sheet
Total Assets
aa.aaaa.aaaa.aaaa.aaaa.aa12,912,29313,178,01813,957,75015,108,79214,248,344
Total Current Liabilities
aa.aaaa.aaaa.aaaa.aaaa.aa1,773,1762,145,7302,481,9402,313,1032,506,521
Total Equity
aa.aaaa.aaaa.aaaa.aaaa.aa5,177,1775,683,5236,354,6717,274,0056,935,979
Cash Flow
Levered Free Cash Flow
aa.aaaa.aaaa.aaaa.aaaa.aa783,892.63929,110.75480,296.75119,406.88735,616.63
Cash from Operations
aa.aaaa.aaaa.aaaa.aaaa.aa1,010,9311,123,105977,156716,3441,057,182
Cash from Investing
aa.aaaa.aaaa.aaaa.aaaa.aa393,530-198,125-607,102-463,862-367,060
Cash from Financing
aa.aaaa.aaaa.aaaa.aaaa.aa-1,088,354-1,070,265-709,148-354,416-751,425
Net Change in Cash
aa.aaaa.aaaa.aaaa.aaaa.aa328,608-116,527-316,165-75,730-72,688
* In Millions of JPY (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 68.36%
Dividend Yield
4.62%
Industry Median 2.37%
Annualised payout
198.00
Paid unevenly
5-Years Growth
+1.72%
Growth Streak
Unlock

Analyst Ratings

9 Buy
7 Hold
0 Sell
Ratings:
16 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 4,965.3
(+15.58% Upside)

Earnings

Latest Release
May 08, 2025
EPS / Forecast
-66.00 / -42.80
Revenue / Forecast
1.0534T / 1.06205T
EPS Revisions
a
a
Unlock
Last 90 days

FAQ

What were Takeda Pharmaceutical's earnings for the latest quarter?

The Takeda Pharmaceutical EPS (TTM) is 68.36. Takeda Pharmaceutical reported sales of 1,053,399.00, net income of -103,155.00, and EPS of -66.00 for the latest quarter.

What was Takeda Pharmaceutical's net income for the latest quarter?

Takeda Pharmaceutical's net income for the latest quarter was -103,155.00.

How did Takeda Pharmaceutical's performance compare year-over-year in the latest quarter?

The company's revenue moved from 1,144,124.00 in the previous quarter to 1,053,399.00 in the latest quarter, and net income moved from 23,789.00 to -103,155.00 compared to the previous quarter.

What is Takeda Pharmaceutical's net profit margin on a TTM basis?

Takeda Pharmaceutical's trailing twelve months (TTM) net profit margin is 2.36%.

How does Takeda Pharmaceutical's debt to equity ratio compare to industry standards?

Takeda Pharmaceutical's total debt-to-equity ratio is 73.37%.

What is Takeda Pharmaceutical's return on investment on a TTM basis?

Takeda Pharmaceutical's trailing twelve months (TTM) return on investment (ROI) is 1.52%.

Did Takeda Pharmaceutical gain or lose cash last quarter?

In the latest quarter, Takeda Pharmaceutical's net change in cash was -109,014.00 million.

What were Takeda Pharmaceutical's total assets and liabilities in the latest quarter?

As of the latest quarter, Takeda Pharmaceutical reported total assets of 14,248,344.00 million and total liabilities of 2,506,521.00 million.

How has Takeda Pharmaceutical's total revenue grown this year?

Takeda Pharmaceutical's total revenue was 1,144,124.00 in the previous quarter and 1,053,399.00 in the latest quarter.

What is Takeda Pharmaceutical's gross margin on a TTM basis?

Takeda Pharmaceutical's trailing twelve months (TTM) gross margin is 65.70%.

What was Takeda Pharmaceutical's revenue per share for the latest quarter?

Takeda Pharmaceutical's revenue per share for the latest quarter was 1,838.08.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.